<TEXT>&#2;<DATELINE>2015-04-30</DATELINE><TITLE>Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use</TITLE><BODY>Abstract The clinical exploitation of type I interferon (IFN) as an antiviral and antineoplastic agent is based on the properties originally attributed to this cytokine family, with schedules reflecting only their antiviral and antiproliferative activities. Nevertheless, type I IFN has emerged as a central activator of the innate immunity. As current schedules of treatment for chronic hepatitis C and for hematological and solid tumors, based on the continuous administration of recombinant type I IFN or pegylated formulations, disregard viral resistance, host genetic variants predicting treatment outcome and mechanisms of refractoriness, new administration schedules, the combination of type I IFN with new drugs and the increased monitoring of patientsâ€™ susceptibility to type I IFN are expected to provide a new life to this valuable cytokine.&#3;</BODY></TEXT>